The JMY Knockout A-549 Polyclonal Cells are a heterogeneous population of human A-549 cells subjected to CRISPR/Cas9-mediated disruption of the JMY gene. This polyclonal knockout product comprises a mixture of edited alleles, providing a loss-of-function model for studying JMY-dependent processes without selection for a single homozygous clone. The polyclonal format facilitates the study of gene function in a more cellular context that mirrors the genetic variability of a population rather than a single clonal derivative. Researchers can employ these cells to interrogate the collective consequences of JMY ablation in a lung adenocarcinoma background.
The parental A-549 cell line was originally derived from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a widely used model of human alveolar basal epithelial cells. These cells exhibit characteristics of type II pneumocytes and are employed to investigate pulmonary epithelial biology, oncogenic transformation, and therapeutic responses. The A-549 line retains functional p53 and is therefore suitable for exploring p53-dependent signaling networks, making it an ideal host for studying the transcriptional cofactor JMY.
JMY is a multifaceted protein that operates at the nexus of transcriptional regulation and actin dynamics. As a p53 cofactor, JMY enhances the expression of pro-apoptotic genes such as Bax and Puma following DNA damage, thereby promoting programmed cell death. This activity is mediated through interactions with p53 and the histone acetyltransferase p300/CBP. Independently of its transcriptional role, JMY nucleates actin polymerization via the Arp2/3 complex, contributing to the reorganization of the actin cytoskeleton, cell motility, and adhesion. Consequently, JMY integrates signals from cellular stress and DNA damage responses to modulate both apoptotic and migratory behaviors.
In the A-549 lung cancer context, JMY??s dual functionality is particularly relevant. Dysregulation of p53 signaling and evasion of apoptosis are hallmarks of lung adenocarcinoma, and JMY??s role in these pathways positions it as a critical node. Moreover, remodeling of the actin cytoskeleton is essential for cancer cell invasion and metastasis. Thus, the JMY Knockout A-549 Polyclonal Cells offer a powerful tool to dissect the contributions of JMY to p53-mediated apoptosis and actin-based motility in a disease-relevant setting, potentially uncovering vulnerabilities for therapeutic intervention.
These cells are suitable for a broad array of experimental applications. Researchers can employ western blotting and RT-qPCR to validate knockdown and monitor expression changes in downstream targets such as Bax, Puma, and components of the Arp2/3 complex. Functional assays including annexin V staining for apoptosis and wound healing or transwell migration assays can delineate JMY??s role in cell death and motility. Immunofluorescence and co-immunoprecipitation enable visualization and confirmation of JMY interactions with actin and the Arp2/3 complex. Additionally, phospho-signaling analyses and drug sensitivity screens can explore how JMY loss influences p53 pathway activation and response to chemotherapeutics. For further technical details and ordering information, please contact Ascent Research.
